News Cessatech A/S

Equities

CESSA

DK0061411964

End-of-day quote NORDIC GROWTH MARKET Other stock markets 23:00:00 29/04/2024 BST			5-day change	1st Jan Change
6.36 ^DKK	+0.32%		+2.58%	-12.40%

02-29	Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

A short business update	04-18	AQ
Minutes from the Annual General Meeting in Cessatech A/S	03-27	AQ
Annual General Meeting - 27 March 2024	03-11	AQ
Cessatech A/S publishes Annual Report for the fiscal year 2023	02-29	AQ
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
CESSATECH ANNOUNCES RESULT OF WARRANT EXERCISE FOR WARRANTS OF SERIES TO2	01-30	AQ
LAST DAY OF TRADING IN WARRANTS OF SERIES TO2 IN CESSATECH IS TOMORROW, JANUARY 24, 2024	01-23	AQ
CESSATECH ANNOUNCES THAT MANAGEMENT AND BOARD HAVE EXERCISED ALL THEIR WARRANTS OF SERIES TO2	01-22	AQ
CESSATECH ANNOUNCES THE START OF THE EXERCISE PERIOD FOR WARRANTS OF SERIES TO2	01-12	AQ
CESSATECH ANNOUNCES TO2 WARRANT EXERCISE PRICE AND START OF EXERCISE PERIOD	01-11	AQ
Q&A session related topline data Study 0205	01-04	AQ
Cessatech: Cessatech announces positive topline data from study 0205 with its lead candidate CT001 for the treatment of pain in children supporting further advancement of CT001	12-22	PU
Third Quarter Report Q3-2023	11-16	AQ
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children	25/10/23	AQ
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	25/10/23	CI
Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001	21/09/23	AQ
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	21/09/23	CI
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%	12/09/23	MT
Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children	12/09/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cessatech A/S

Equities

CESSA

DK0061411964

Summary

Filters